Kane Biotech Inc.
KNBIF
$0.03
$0.0024.38%
OTC PK
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -89.18% | -116.91% | -99.34% | -95.54% | 646.49% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -89.18% | -116.91% | -99.34% | -95.54% | 646.49% |
| Cost of Revenue | -86.86% | -113.53% | -98.13% | -72.05% | 2,830.68% |
| Gross Profit | -109.46% | 108.67% | -100.90% | -112.49% | -0.34% |
| SG&A Expenses | -49.57% | 60.80% | -62.00% | -85.88% | 12.53% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -53.01% | -35.10% | -71.15% | -82.59% | 19.21% |
| Operating Income | 40.15% | 22.49% | 11.96% | 75.30% | 8.19% |
| Income Before Tax | 39.81% | 39.28% | 11.37% | 71.66% | 23.38% |
| Income Tax Expenses | -- | 91.72% | -- | -- | -- |
| Earnings from Continuing Operations | 39.46% | -341.56% | 11.37% | 71.66% | 23.38% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 39.46% | 49.29% | 0.72% | -103.75% | 17.99% |
| EBIT | 40.15% | 22.49% | 11.96% | 75.30% | 8.19% |
| EBITDA | 39.35% | 21.20% | 21.83% | 78.39% | 7.78% |
| EPS Basic | 50.88% | 70.27% | 58.06% | -102.95% | 27.85% |
| Normalized Basic EPS | 48.57% | 56.76% | 63.64% | 76.19% | 33.96% |
| EPS Diluted | 60.00% | -7.69% | 81.43% | -103.67% | 11.39% |
| Normalized Diluted EPS | 48.57% | 56.76% | 63.64% | 74.29% | 33.96% |
| Average Basic Shares Outstanding | 21.19% | 73.33% | 136.15% | 23.17% | 13.81% |
| Average Diluted Shares Outstanding | 21.19% | 73.33% | 136.15% | 14.24% | 13.81% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |